Premium
pRb2/p130 Protein expression is correlated with clinicopathologic findings in patients with oral squamous cell carcinoma
Author(s) -
Tanaka Nobuyuki,
Ogi Kazuhiro,
Odajima Tetsuyo,
Dehari Hironari,
Yamada Shunpei,
Sonoda Tomoko,
Kohama Geniku
Publication year - 2001
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(20011015)92:8<2117::aid-cncr1553>3.0.co;2-o
Subject(s) - medicine , malignancy , carcinoma , pathology , oncology
BACKGROUND pRb2/p130 is one of the retinoblastoma (Rb) gene family and a suppressor oncogene. Immunohistochemically, the expression of pRb2/p130 was reported to be correlated inversely with the degree of malignancy in lung carcinoma and endometrial carcinoma. In the current study, the correlation between expression of pRb2/p130 and clinicopathologic factors in oral squamous cell carcinoma was investigated. METHODS One hundred twenty‐two specimens from patients with oral squamous cell carcinoma were investigated by staining with a polyclonal antibody against pRb2/p130. The correlation between the expression of pRb2/p130 and various clinicopathologic factors was studied. RESULTS Positive staining for pRb2/p130 was observed in 61 of 122 cases (50.0%). pRb2/p130 expression was found to be correlated significantly with clinical stage ( P = 0.050), cervical lymph node metastasis ( P = 0.035), and tumor differentiation ( P = 0.050). In the entire group a significantly reduced 5‐year cumulative survival rate was observed in patients with pRb2/p130‐negative tumors compared with patients whose tumors positively expressed pRb2/p130 ( P = 0.0004). When tested with Cox proportional hazards regression analysis, the most significant independent prognostic factor for the entire group of 122 patients was found to be pRb2/p130 expression. CONCLUSIONS Expression of pRb2/p130 may be a good prognostic indicator in patients with oral squamous cell carcinoma and also may be utilized for the subclassification of tumors with the Grade 3 mode of carcinoma invasion. Cancer 2001;92:2117–25. © 2001 American Cancer Society.